Genomic Health

• Mega-Hedge Fund Focusing on the Life Sciences

  By Meena Krishnamsetty - April 18, 2013 | Tickers: GHDX, INCY, PCYC, SGEN, GEVA

  The $3+ billion Baker Brothers Advisors equity portfolio, managed by brothers Julian and Felix Baker, focuses almost exclusively on life science companies with a small to medium sized market capitalization.

  Why should you watch hedge funds?

  Insider Monkey looks at 450 of the world’s most elite hedge fund managers and our research has shown that over time their picks routinely outperform. Let’s look at the top five picks more »

• Mega-Hedge Fund Focusing on The Life Sciences

  By Meena Krishnamsetty - April 16, 2013 | Tickers: GHDX, INCY, PCYC, SGEN, GEVA

  The $3+ billion Baker Brothers Advisors equity portfolio, managed by brothers Julian and Felix Baker, focuses almost exclusively on life science companies with a small to medium sized market capitalization.

  Why should you watch hedge funds?

  Insider Monkey looks at 450 of the world’s most elite hedge fund managers and our research has shown that over time, their picks routinely outperform. For more than a decade in our back more »

• Personalized Diagnostic Medicine Coming of Age

  By Streetwise Reports - December 6, 2012 | Tickers: EXAS, GHDX, OPK

  By George S. Mack of The Life Sciences Report.

  For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.

  As little as a decade ago we were all thinking in terms of one blood draw being the be-all and end-all of diagnostics. With the first human genome sequenced, it would only require a panel of genetic, epigenetic, proteomic and small molecule metabolic more »

• Avoid This One-Trick Pony and Get a LIFE Instead

  By Robert Zimmerman - November 6, 2012 | Tickers: BMY, GHDX, ILMN, LIFE

  After enjoying positive earnings and a recent contract with CIGNA insurance, Genomic Health (NASDAQ: GHDX) seemed poised to grow like a weed.  Riding the success of its Oncotype DX assay for invasive breast cancer, Genomic Health was profitable and its stock was moving higher.  The future promised more.  Now, it might not happen.  Published research over the past year or so hasn’t looked kindly on Genomic Health’s more »

• Genomic Health: Advantage Lost

  By Robert Zimmerman - October 22, 2012 | Tickers: GHDX |

  Earlier this year, a physician I know who specializes in medical genetic testing told me that in 2001, it was possible to sequence every gene in a human cell at a cost of $100 million.  Today, she can do the same thing for less than $3,000.  And the price continues to drop. 

  This precipitous decline in the cost of genetic testing has opened a potentially huge door for the more »

• A Diagnostic Review of My Healthcare Watch List

  By Matthew DiLallo - July 16, 2012 | Tickers: CTRX, CVS, ESRX, GHDX, MPW

  Having just surgically removed a company from my watch list, I didn’t want to let too much time pass before filling that hole.  By using a combination of options strategies and mixing it with soon to be delivered dividend income, the little paper trading portfolio that I like to call the “No Drip, No Mess” Portfolio is getting ready to grow. Because health care plays such a vital role more »

• Beating the Blues: Darden Restaurants and Genomic Health

  By Declan Fallon - May 22, 2012 | Tickers: DRI, GHDX

  It's a tough market to be searching for confidence-boosting stocks, but a few candidates are doing their bit. These are two stocks which were able to break to new multi-year highs on higher volume last week. Both have held up well to the selling in the broader market and both are well positioned to lead when buyers make their eventual return.

  Darden Restaurants (NYSE: DRI) made a break for more »

• Excellent Science + Unmet Need Equal Great Returns

  By Streetwise Reports - May 21, 2012 | Tickers: CRIS, GHDX, ISIS, MAKO, NXTM

  By George S. Mack, The Life Sciences Report

  Short-term gains come with pipeline products in mid-stage development.

  It is satisfying on those rare occasions when I get a straight answer to my first question in an interview for The Life Sciences Report. "Our theme is to focus on the markets with the most profit potential," answers Chief Investment Strategist Alex Daley of Casey's Extraordinary Technology. Daley has had some more »

• A Scientist Finds Treasure Researching Oncology Drugs

  By Streetwise Reports - April 2, 2012 | Tickers: ALXN, GHDX, GSK, SPPI, THLD

  George S. Mack, The Life Sciences Report

  Oncology Drugs Rack Up Gains

  I love finding out how people move from point A to point B in their careers. It was an incremental process for George Zavoico who is today a senior equity analyst at New York City-based MLV & Co., a boutique investment bank focusing on the small cap space. Armed with his Ph.D. in physiology, Zavoico loves the research more »

• You Look Good in those Genes!

  By Damon Judd - February 23, 2012 | Tickers: GHDX, ILMN, LIFE |

  I’m going to make a bold prediction that genetic sequencing will be the “next big thing” in medical research and treatment technology. A decade after the first draft of the human genome was published, hospitals and clinics are using DNA sequencing to generate better treatments and diagnoses for patients with rare childhood diseases, cancers and other mysterious conditions.

  Now that the puzzle of the human genome has been solved more »

• J.P. Morgan Healthcare Conference Schedule: Day One

  By Brandy Betz - January 8, 2012 | Tickers: ARAY, ACOR, A, ALGN, AMRN, AMGN, AMLN, ARTC, BIIB, BMRN, BRKR, CFN, CTRX, CELG, CNC, COV, DNDN, XRAY, EW, ENDP, EPOC, ESRX, GHDX, GILD, HLS, HTWR, HMSY, HGSI, IDXX, IPXL, INCY, IRWD, MCK, MRX, MDT, MR, MOH, MYL, NVS, ONXX, PRX, PRGO, QSII, REGN, RMD, RIGL, SGEN, ST, SIAL, THC, MDCO, THOR, VRTX, VVUS, WAT, WMGI, ZLTQ

  The 30th Annual J.P. Morgan Healthcare Conference kicks off with a full day of presentations from companies that range from global pharmaceutical leaders to small cap novel pharmaceutical developers and health technology manufacturers. The majority of the presentations will be available through live webcasts with archived replay offered later in the day.

  I will be following (and covering) the novel therapeutic companies that have caught my eye. VIVUS (NASDAQ: VVUSmore »)